Citigroup
AKBA icon

Citigroup’s Akebia Therapeutics AKBA Stock Holding History

Citigroup’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,478
Closed -$22K – 7578
2019
Q4 		$22K Hold
3,478
– – ﹤0.01% 6884
2019
Q3 		$14K Sell
3,478
-1,147
-25% -$4.92K ﹤0.01% 6902
2019
Q2 		$22K Sell
4,625
-9,357
-67% -$53.2K ﹤0.01% 7033
2019
Q1 		$115K Buy
13,982
+2,845
+26% +$19.5K ﹤0.01% 5603
2018
Q4 		$62K Buy
+11,137
New +$87.2K ﹤0.01% 6050

Other funds holding AKBA

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Choreo LLC
Choreo LLC Rockford, Illinois $9.7B AUM 18.43% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
PFG Private Wealth Management
PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return

Citigroup's AKBA Position: Q3 2026 in Review

Citigroup reduced its Akebia Therapeutics (AKBA) stake by 99% in Q3 2026, selling an estimated $1.19M and leaving 14,482 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5114.

Citigroup first reported a position in AKBA in Q2 2014 and has held it in 50 quarters since. The position peaked at $8.26M in Q2 2020. 50 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Citigroup held 14,482 shares of Akebia Therapeutics worth $13.3K as of Q3 2026.
  • Citigroup sold 1,110,088 Akebia Therapeutics shares in Q3 2026, an estimated $1.19M.
  • Akebia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5114 holding.
  • Citigroup first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 50 quarters since.
  • Citigroup's Akebia Therapeutics position peaked at $8.26M in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.